Among 262 patients treated with NAT followed by axillary lymph node dissection (ALND), baseline cN+ status, HR+/HER2− tumor subtype, and larger post-NAT tumor size emerged as independent predictors of ypN2-3 disease. This evidence concerns the gene HR and neoplasm.